Browse > Article
http://dx.doi.org/10.3904/kjm.2014.87.4.484

A Case Report of Recurrent Malignant Paraganglioma with Lung and Spine Metastasis that Occurred Sixteen Years after Primary Tumor Excision  

Moon, Eul Sun (Department of Internal Medicine, Korea University College of Medicine)
Min, Hye Sook (Department of Internal Medicine, Korea University College of Medicine)
Jung, Chang Ho (Department of Internal Medicine, Korea University College of Medicine)
Choi, Jong Hyun (Department of Internal Medicine, Korea University College of Medicine)
Kim, Jun Suk (Department of Internal Medicine, Korea University College of Medicine)
Yoo, Hye Jin (Department of Internal Medicine, Korea University College of Medicine)
Choi, Sang Yong (Department of Surgery, Korea University College of Medicine)
Publication Information
The Korean Journal of Medicine / v.87, no.4, 2014 , pp. 484-490 More about this Journal
Abstract
Paragangliomas are rare tumors that arise from the extra-adrenal chromaffin cells, and malignancy is defined by the presence of metastases to sites that normally lack chromaffin tissue. The main therapeutic targets are tumor reduction and control of excessive catecholamine secretion. Currently, the adjuvant therapy to surgery is radiotherapy treatment using high-dose MIBG; chemotherapy is currently evolving. We report herein a case of malignant paraganglioma with lung and spine metastasis that occurred 16 years after primary tumor excision and was treated with high dose MIBG radiotherapy and chemotherapy.
Keywords
Malignant paraganglioma, Lung metastasis, Spine metastasis; Metaiodobenzylguanidine; Chemotherapy;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Goffredo P, Sosa JA, Roman SA. Malignant pheochromocytoma and paraganglioma: a population level analysis of long-term survival over two decades. J Surg Oncol 2013;107:659-664.   DOI   ScienceOn
2 Chrisoulidou A, Kaltsas G, Ilias I, Grossman AB. The diagnosis and management of malignant phaeochromocytoma and paraganglioma. Endocr Relat Cancer 2007;14:569-585.   DOI   ScienceOn
3 Strong VE, Kennedy T, Al-Ahmadie H, et al. Prognostic indicators of malignancy in adrenal pheochromocytomas: clinical, histopathologic, and cell cycle/apoptosis gene expression analysis. Surgery 2008;143:759-768.   DOI   ScienceOn
4 Andersen KF, Altaf R, Krarup-Hansen A, et al. Malignant pheochromocytomas and paragangliomas - the importance of a multidisciplinary approach. Cancer Treat Rev 2011;37:111-119.   DOI   ScienceOn
5 Maithel SK, Fong Y. Hepatic ablation for neuroendocrine tumor metastases. J Surg Oncol 2009;100:635-638.   DOI   ScienceOn
6 Ayala-Ramirez M, Palmer JL, Hofmann MC, et al. Bone metastases and skeletal-related events in patients with malignant pheochromocytoma and sympathetic paraganglioma. J Clin Endocrinol Metab 2013;98:1492-1497.   DOI   ScienceOn
7 Gonias S, Goldsby R, Matthay KK, et al. Phase II study of high-dose [131I] metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma. J Clin Oncol 2009;27:4162-4168.   DOI   ScienceOn
8 Tanabe A, Naruse M, Nomura K, Tsuiki M, Tsumagari A, Ichihara A. Combination chemotherapy with cyclophosphamide, vincristine, and dacarbazine in patients with malignant pheochromocytoma and paraganglioma. Horm Cancer 2013;4:103-110.   DOI   ScienceOn
9 Joshua AM, Ezzat S, Asa SL, et al. Rationale and evidence for sunitinib in the treatment of malignant paraganglioma/ pheochromocytoma. J Clin Endocrinol Metab 2009;94:5-9.   DOI   ScienceOn
10 Ayala-Ramirez M, Feng L, Habra MA, et al. Clinical benefits of systemic chemotherapy for patients with metastatic pheochromocytomas or sympathetic extra-adrenal paragangliomas: insights from the largest single-institutional experience. Cancer 2012;118:2804-2812.   DOI   ScienceOn